Literature DB >> 30487288

Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses.

Ewa M Kosciuczuk1,2,3, Swarna Mehrotra1,2, Diana Saleiro1,2, Barbara Kroczynska1,4, Beata Majchrzak-Kita5, Pawel Lisowski6,7,8, Caroline Driehaus1, Anna Rogalska1, Acara Turner1, Thomas Lienhoop1, David Gius1,4, Eleanor N Fish5, Athanassios Vassilopoulos1,4, Leonidas C Platanias9,2,3.   

Abstract

Type I interferons (IFNs) induce expression of multiple genes that control innate immune responses to invoke both antiviral and antineoplastic activities. Transcription of these interferon-stimulated genes (ISGs) occurs upon activation of the canonical Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathways. Phosphorylation and acetylation are both events crucial to tightly regulate expression of ISGs. Here, using mouse embryonic fibroblasts and an array of biochemical methods including immunoblotting and kinase assays, we show that sirtuin 2 (SIRT2), a member of the NAD-dependent protein deacetylase family, is involved in type I IFN signaling. We found that SIRT2 deacetylates cyclin-dependent kinase 9 (CDK9) in a type I IFN-dependent manner and that the CDK9 deacetylation is essential for STAT1 phosphorylation at Ser-727. We also found that SIRT2 is subsequently required for the transcription of ISGs and for IFN-driven antiproliferative responses in both normal and malignant cells. These findings establish the existence of a previously unreported signaling pathway whose function is essential for the control of JAK-STAT signaling and the regulation of IFN responses. Our findings suggest that targeting sirtuin activities may offer an avenue in the development of therapies for managing immune-related diseases and cancer.

Entities:  

Keywords:  SIRT2; STAT1; cytokine; deacetylation; histone deacetylase (HDAC); immune regulation; innate immunity; interferon; post-translational modification (PTM); signal transducers and activators of transcription 1 (STAT1); signal transduction; sirtuin; type I IFN

Mesh:

Substances:

Year:  2018        PMID: 30487288      PMCID: PMC6341380          DOI: 10.1074/jbc.RA118.005956

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity.

Authors:  Hao-Ming Chang; Matthew Paulson; Michelle Holko; Charles M Rice; Bryan R G Williams; Isabelle Marié; David E Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

2.  Critical roles for Rictor/Sin1 complexes in interferon-dependent gene transcription and generation of antiproliferative responses.

Authors:  Surinder Kaur; Barbara Kroczynska; Bhumika Sharma; Antonella Sassano; Ahmet Dirim Arslan; Beata Majchrzak-Kita; Brady L Stein; Brandon McMahon; Jessica K Altman; Bing Su; Raffaele A Calogero; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

3.  The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase.

Authors:  Brian J North; Brett L Marshall; Margie T Borra; John M Denu; Eric Verdin
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

4.  Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis.

Authors:  Hyun-Seok Kim; Cuiying Xiao; Rui-Hong Wang; Tyler Lahusen; Xiaoling Xu; Athanassios Vassilopoulos; Guelaguetza Vazquez-Ortiz; Won-Il Jeong; Ogyi Park; Sung Hwan Ki; Bin Gao; Chu-Xia Deng
Journal:  Cell Metab       Date:  2010-09-08       Impact factor: 27.287

5.  SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys310.

Authors:  Karin M Rothgiesser; Süheda Erener; Susanne Waibel; Bernhard Lüscher; Michael O Hottiger
Journal:  J Cell Sci       Date:  2010-11-16       Impact factor: 5.285

6.  Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.

Authors:  K Yanagisawa; H Yamauchi; M Kaneko; H Kohno; H Hasegawa; S Fujita
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

7.  Acetylation-dependent signal transduction for type I interferon receptor.

Authors:  Xiaoli Tang; Jin-Song Gao; Ying-jie Guan; Katya E McLane; Zheng-Long Yuan; Bharat Ramratnam; Y Eugene Chin
Journal:  Cell       Date:  2007-10-05       Impact factor: 41.582

8.  Role of p38alpha Map kinase in Type I interferon signaling.

Authors:  Yongzhong Li; Antonella Sassano; Beata Majchrzak; Dilip K Deb; David E Levy; Matthias Gaestel; Angel R Nebreda; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2003-10-24       Impact factor: 5.157

9.  Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain.

Authors:  Iwona Sadzak; Melanie Schiff; Irene Gattermeier; Reingard Glinitzer; Ines Sauer; Armin Saalmüller; Edward Yang; Barbara Schaljo; Pavel Kovarik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

10.  SIRT2 directs the replication stress response through CDK9 deacetylation.

Authors:  Hui Zhang; Seong-Hoon Park; Brooke G Pantazides; Oleksandra Karpiuk; Matthew D Warren; Claire W Hardy; Duc M Duong; So-Jeong Park; Hyun-Seok Kim; Athanassios Vassilopoulos; Nicholas T Seyfried; Steven A Johnsen; David Gius; David S Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

View more
  11 in total

Review 1.  Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.

Authors:  Diana Saleiro; Leonidas C Platanias
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

Review 2.  Targeting cyclin-dependent kinase 9 in cancer therapy.

Authors:  Yi-Li Shen; Yan-Mao Wang; Ya-Xin Zhang; Shen-Jie Ma; Le-He Yang; Cheng-Guang Zhao; Xiao-Ying Huang
Journal:  Acta Pharmacol Sin       Date:  2021-11-22       Impact factor: 7.169

3.  Gestation and breastfeeding in schistosomotic mice differentially alters the expression of histone deacetylases (HDACs) in adult offspring.

Authors:  Gabriela Calixto Ribeiro de Holanda; Fabrício Oliveira Souto; Maria da Conceição Silva; Virgínia Maria Barros de Lorena; Vlaudia Maria Assis Costa; Monica Camelo Pessôa de Azevedo Albuquerque; Valdênia Maria Oliveira de Souza; José Luiz de Lima Filho
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-02-03       Impact factor: 2.743

Review 4.  Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways.

Authors:  Candice Mazewski; Ricardo E Perez; Eleanor N Fish; Leonidas C Platanias
Journal:  Front Immunol       Date:  2020-11-23       Impact factor: 7.561

5.  CDK8 Fine-Tunes IL-6 Transcriptional Activities by Limiting STAT3 Resident Time at the Gene Loci.

Authors:  Jonathan Martinez-Fabregas; Luopin Wang; Elizabeth Pohler; Adeline Cozzani; Stephan Wilmes; Majid Kazemian; Suman Mitra; Ignacio Moraga
Journal:  Cell Rep       Date:  2020-12-22       Impact factor: 9.423

6.  Host sirtuin 2 as an immunotherapeutic target against tuberculosis.

Authors:  Ashima Bhaskar; Santosh Kumar; Mehak Zahoor Khan; Amit Singh; Ved Prakash Dwivedi; Vinay Kumar Nandicoori
Journal:  Elife       Date:  2020-07-22       Impact factor: 8.140

7.  AFF1 acetylation by p300 temporally inhibits transcription during genotoxic stress response.

Authors:  Nidhi Kumari; M Abul Hassan; Xiangdong Lu; Robert G Roeder; Debabrata Biswas
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

Review 8.  The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.

Authors:  Guo Li; Yuan Tian; Wei-Guo Zhu
Journal:  Front Cell Dev Biol       Date:  2020-09-29

9.  Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.

Authors:  Lehe Yang; Feng Zhou; Yan Zhuang; Yanan Liu; Lingyuan Xu; Haiyang Zhao; Youqun Xiang; Xuanxuan Dai; Zhiguo Liu; Xiaoying Huang; Liangxing Wang; Chengguang Zhao
Journal:  Br J Cancer       Date:  2020-10-30       Impact factor: 7.640

Review 10.  Type I and II Interferons in the Anti-Tumor Immune Response.

Authors:  Sarah E Fenton; Diana Saleiro; Leonidas C Platanias
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.